Mordin M, Bhogal P, Warttig S, Gildea L, Long J, D'Souza V, Kinderas M, Ling C, Hartley L. HTA requirements for medical technologies in Canada. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA.
Mordin M, Bhogal P, Warttig S, Gildea L, Long J, D'Souza V, Kinderas M, Ling C, Hartley L. What is the medical technology HTA process in Japan? Poster presented at the ISPOR 2024; May 6, 2024. Atlanta, GA.
Hartley L, Gildea L, Mordin M, Long J, D'Souza V, Kinderås M, Ling C, Warttig S. Does real-world evidence play a role in decision-making by HTA bodies for medical technologies? Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplement):S434-5. doi: 10.1016/j.jval.2023.09.2271
Warttig S, Ling C. Health technology assessment (HTA) methods for monoclonal antibodies for treatment and prevention of COVID-19. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S301. doi: 10.1016/j.jval.2022.09.1486